TY  - JOUR
AU  - Hidalgo, M.
AU  - Plaza Hernández, José Carlos
AU  - Musteanu, Mónica Andrea
AU  - Illei, P.
AU  - Brachmann, C.B.
AU  - Heise, C.
AU  - Pierce, D.
AU  - Lopez Casas, P.P.
AU  - Menendez, C.
AU  - Tabernero, J.
AU  - Romano, A.
AU  - Wei, X.
AU  - López-Ríos Moreno, Fernando
AU  - Von Hoff, D.D.
PY  - 2015
DO  - 10.1158/1078-0432.CCR-14-3222
UR  - https://hdl.handle.net/20.500.14352/117589
T2  - Clinical Cancer Research
AB  - Purpose: nab-Paclitaxel plus gemcitabine was superior to gemcitabine alone for patients with metastatic pancreatic cancer (MPC) in the phase III MPACT trial. This study evaluated the association of secreted protein acidic and rich in cysteine (SPARC)...
LA  - eng
M2  - 4811
PB  - American Association for Cancer Research
TI  - SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial
TY  - journal article
VL  - 21
ER  -